Lenova tablets are indicated in adults for the treatment of the following infections (see sections
4.4 and 5.1):
• Acute bacterial sinusitis
• Acute exacerbations of chronic bronchitis
• Community-acquired pneumonia
• Complicated skin and soft tissue infections.
For the above-mentioned infections Lenova should be used only when it is considered
inappropriate to use antibacterial agents that are commonly recommended for the initial
treatment of these infections.
• Pyelonephritis and complicated urinary tract infections (see section 4.4)
• Chronic bacterial prostatitis,
• Uncomplicated cystitis (see section 4.4)
• Inhalation Anthrax: post exposure prophylaxis and curative treatment (see section 4.4).
Lenova may also be used to complete a course of therapy in patients who have shown
improvement during initial treatment with intravenous levofloxacin.
Consideration should be given to official guidance on the appropriate use of antibacterial agents

Lenova tablets administered once or twice daily.
The dosage depends on the type and severity of the infection and the susceptibility of the
presumed causative pathogen.
Lenova tablets may also be used to complete a course of therapy in patients who have shown
improvement during initial treatment with intravenous levofloxacin; given the bioequivalence of
the parenteral and oral forms, the same dosage can be used.
 

Posology
The following dose recommendations can be given for Lenova:
Dosage in patients with normal renal function (creatinine clearance > 50 ml/min)

Indication	Daily dose regimen (according to severity)	Duration of the treatment (according to severity)
Acute bacterial sinusitis	500 mg once daily	10 – 14 days
Acute bacterial exacerbations of chronic bronchitis	500 mg once daily	7 – 10 days
Community-acquired pneumonia	500 mg once or twice daily	7 – 14 days
Pyelonephritis	500 mg once daily	7 – 10 days
Uncomplicated cystitis	250 mg once daily	3 days
Complicated urinary tract infections	500 mg once daily	7 – 14 days
Chronic bacterial prostatitis	500 mg once daily	28 days
Complicated skin and soft tissue infections	500 mg once or twice daily	7 – 14 days
Inhalation Anthrax	500 mg once daily	8 weeks

Special populations
Impaired renal function (creatinine clearance ≤ 50 ml/min)

Creatinine clearance	Dose regimen
	250 mg/24 h	500 mg/24 h	500 mg/12 h
	first dose: 250 mg	first dose: 500 mg	first dose: 500 mg
50-20 ml/min	then: 125 mg/24 h	then: 250 mg/24 h	then: 250 mg/12 h
19-10 ml/min	then: 125 mg/48 h	then: 125 mg/24 h	then: 125 mg/12 h
< 10 ml/min (including haemodialysis and CAPD)1	then: 125 mg/48 h	then: 125 mg/24 h	then: 125 mg/24 h

¹ No additional doses are required after haemodialysis or continuous ambulatory peritoneal
dialysis (CAPD)

Impaired liver function
No adjustment of dosage is required since levofloxacin is not metabolised to any relevant extent
by the liver and is mainly excreted by the kidneys.
Elderly population
No adjustment of dose is required in the elderly, other than that imposed by consideration of
renal function (see section 4.4 “Tendinitis and tendon rupture” and “QT interval prolongation”).
Paediatric population
Levofloxacin is contraindicated in children and growing adolescents (see section 4.3).
 

Method of administration
Lenova tablets should be swallowed without crushing and with sufficient amount of liquid. They
may be divided at the score line to adapt the dose. The tablets may be taken during meals or
between meals. Lenova tablets should be taken at least two hours before or after iron salts, zinc
salts, magnesium- or aluminium-containing antacids, or didanosine (only didanosine
formulations with aluminium or magnesium containing buffering agents), and sucralfate
administration, since reduction of absorption can occur (see section 4.5).

 

Lenova tablets must not be used: • in patients hypersensitive to levofloxacin, or other quinolones or any of the excipients listed in section 6.1 • in patients with epilepsy, • in patients with history of tendon disorders related to fluoroquinolone administration, • in children or growing adolescents, • during pregnancy, • in breast-feeding women.

The use of Levofloxacin Tablets should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8).

Treatment of these patients with Levofloxacin tablets should only be initiated in the absence of
alternative treatment options and after careful benefit/risk assessment (see also section 4.3).

Aortic aneurysm and dissection, and heart valve regurgitation/incompetence
Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in
elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones, Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).
Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after
consideration of other therapeutic options in patients with positive family history of aneurysm
disease, or congenital heart valve disease, or in patients diagnosed with pre-existing aortic
aneurysm and/or aortic dissection, or heart valve disease, or in presence of other risk factors or
conditions predisposing
- for aortic both aneurysm and dissection and heart valve regurgitation/incompetence (e.g.
connective tissue disorders such as Marfan syndrome or vascular Ehlers-Danlos syndrome, Turner syndrome, Behcet's disease, hypertension, rheumatoid arthritis ).
- for aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sjögren's syndrome) or additionally
- for heart valve regurgitation/incompetence (e.g. infective endocarditis).

The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients
treated concurrently with systemic corticosteroids.
In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.
Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new
onset of heart palpitations, or development of oedema of the abdomen or lower extremities.
Methicillin-resistant S. aureus are very likely to possess co-resistance to fluroquinolones,
including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the
organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).

Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation
of Chronic Bronchitis when these infections have been adequately diagnosed.
Resistance to fluoroquinolones of E. coli – the most common pathogen involved in urinary tract
infections
– varies across the European Union. Prescribers are advised to take into account the local
prevalence of resistance in E. coli to fluoroquinolones.
Inhalation Anthrax: Use in humans is based on in vitro Bacillus anthracis susceptibility data and
on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of Anthrax.

Prolonged, disabling and potentially irreversible serious adverse drug reactions
Very rare cases of prolonged (continuing months or years), disabling and potentially irreversible
serious adverse drug reactions affecting different, sometimes multiple, body systems
(musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving
quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors.
Levofloxacin Tablet should be discontinued immediately at the first signs or symptoms of any
serious adverse reaction and patients should be advised to contact their prescriber for advice

Tendinitis and tendon rupture
Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment in patients receiving daily doses of 1000 mg levofloxacin. The risk of tendonitis and tendon rupture is increased in older patients ,

patients with renal impairment, patients with solid organ transplants, and those treated
concurrently with corticosteroids. Therefore, concomitant use of corticosteroids should be
avoided. At the first sign of tendinitis (e.g. painful swelling, inflammation). treatment with
Levofloxacin tablet should be discontinued and alternative treatment should be considered. The
affected limb(s) should be appropriately treated (e.g. immobilisation). Corticosteroids should not be used if signs of tendinopathy occur

Clostridium difficile-associated disease
Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with
levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium
difficile-associated disease (CDAD). CDAD may range in severity from mild to life threatening,
the most severe form of which is pseudomembranous colitis (see section 4.8). It is therefore
important to consider this diagnosis in patients who develop serious diarrhoea during or after
treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped
immediately and patients should be treated with supportive measure ± specific therapy without
delay (e.g. oral vancomycin). Products inhibiting the peristalsis are contraindicated in this
clinical situation.

Patients predisposed to seizures
Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is
contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other
quinolones, should be used with extreme caution in patients predisposed to seizures or
concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with
levofloxacin should be discontinued.

Patients with glucose-6-phosphate dehydrogenase deficiency
Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be
prone to haemolytic reactions when treated with quinolone antibacterial agents. , and so
levofloxacin should be used with caution Therefore, if levofloxacin has to be used in these
patients, potential occurrence of haemolysis should be monitored.

Patients with renal impairment
Since levofloxacin is excreted mainly by the kidneys, the dose of levofloxacin should be adjusted
in patients with renal impairment (see section 4.2).

Hypersensitivity reactions
Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up
to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should
discontinue treatment immediately and contact their physician or an emergency physician, who
will initiate appropriate emergency measures.

Severe bullous reactions
Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal
necrolysis have been reported with levofloxacin (see section 4.8). Patients should be advised to
contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions
occur.

Dysglycaemia
As with all quinolones, disturbances in blood glucose, including both hyperglycaemia and
hypoglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. there are known cases of hypoglycaemic coma. In diabetic patients, , careful monitoring of blood glucose is recommended (see section 4.8). Treatment with Lenova should be stopped immediately if a patient reports blood glucose disturbance and alternative nonfluoroquinolone antibacterial therapy should be considered

Prevention of photosensitisation
Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or artificial UV rays (e.g. sunray lamp or solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.

Patients treated with vitamin K antagonists
Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with
levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should
be monitored when these drugs are given concomitantly (see section 4.5).

Psychotic reactions
Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin.
In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour,
sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures
instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in
patients with a history of psychiatric disease.

QT interval prolongation
Caution should be taken when using fluroquinolones, including levofloxacin, in patients with
known risk factors for prolongation of the QT interval such as, for example:
- congenital long QT syndrome
- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III
antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)
- uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)
- cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)
Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore,
caution should be taken when using fluoroquinolones, including levofloxacin, in these
populations (see sections 4.2 Elderly, 4.5, 4.8 and 4.9).

Peripheral neuropathy
Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypaesthesia,
dysesthesia, or weakness have been reported in patients receiving fluoroquinolones.Patients under
treatment with Levofloxacin Tablets should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition. (see section 4.8).

Hepatobiliary disorders
Cases of hepatic necrosis up to life-threatening hepatic failure have been reported with
levofloxacin, primarily in patients with severe underlying diseases e.g. sepsis (see section 4.8).
Patients should be advised to stop treatment and contact their doctor if signs and symptoms of
hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.

Exacerbation of myasthenia gravis
Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may
exacerbate muscle weakness in patients with myasthenia gravis. Post marketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated
with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.

Vision disorders
If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).

Superinfection
The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible
organisms. If superinfection occurs during therapy, appropriate measures should be taken.

Interference with laboratory test
In patients treated with levofloxacin, determination of opiates in urine may give false-positive
results. It may be necessary to confirm positive opiate screens by more specific method.
Levofloxacin may inhibit the growth of Mycobacterium tuberculosis and, therefore, may give
false-negative results in the bacteriological diagnosis of tuberculosis.
This medicinal product contains the colouring agent sunset yellow (E110), which may cause
allergic reactions.

Effect of other medicinal products on levofloxacin
Iron salts, zinc salts, magnesium- or aluminium-containing antacid, didanosines

Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium-
containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium

containing buffering agents) are administered concomitantly with Lenova tablets. Concurrent
administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their
oral absorption. It is recommended that preparations containing divalent or trivalent cations
such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, didanosine (only
didanosine formulations with aluminium or magnesium containing buffering agents) should not
be taken 2 hours before or after Lenova tablet administration (see section 4.2). Calcium salts
have a minimal effect on the oral absorption of levofloxacin.
Sucralfate
The bioavailability of Lenova tablets is significantly reduced when administered together with
sucralfate. If the patient is to receive both sucralfate and levofloxacin, it is best to administer
sucralfate 2 hours after the levofloxacin administration (see section 4.2).
Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs
No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study.
However a pronounced lowering of the cerebral seizure threshold may occur when quinolones
are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold. Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.
Probenecid and cimetidine
Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin.
The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%).
This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin.
However, at the tested doses in the study, the statistically significant kinetic differences are
unlikely to be of clinical relevance. Caution should be exercised when levofloxacin is coadministered with drugs that aeffect the tubular renal secretion such as probenecid and
cimetidine, especially in renal impaired patients.
Other relevant information
Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not
affected to any clinically relevant extent when levofloxacin was administered together with the
following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.

Effect of levofloxacin on other medicinal products
Ciclosporin
The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.
Vitamin K antagonists
Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported
in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin).
Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists
(see section 4.4).
Drugs known to prolong QT interval
Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving
drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic
antidepressants, macrolides, antipsychotics) (see section 4.4 QT interval prolongation).
 

Other relevant information
In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of
theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a
CYP1A2 inhibitor.
 

Other forms of interactions
Food
There is no clinically relevant interaction with food. Lenova tablets may therefore be administered regardless of food intake.

Pregnancy
There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However, in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see section 4.2 and 5.3).
Breast-feeding
Lenova is contraindicated in breast-feeding women. There is insufficient information on the
excretion of levofloxacin in human milk; however other fluoroquinolones are excreted in breast
milk. In the absence of human data and due to the experimental data suggests risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).
Fertility
Levofloxacin caused no impairment of fertility or reproductive performance in rats.

Lenova has moderate influence on the ability to drive and use machines. Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient's ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).

The information given below is based on data from clinical studies in more than 8,300 patients
and on extensive post marketing experience.
Frequencies are defined using the following convention:
Very common (≥1/10)
Common (≥1/100 to <1/10)
Uncommon (≥1/1,000 to<1/100)
Rare (≥1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data).
Within each frequency grouping, undesirable effects are presented in order of decreasing
seriousness.

System organ class	Common (≥1/100 to <1/10)	Uncommon (≥1/1,000 to <1/100)	Rare (≥1/10,000 to < 1/1,000)	Not known (cannot be estimated from available data)
Infections and infestations		Fungal infection Including Candidia infection Pathogen resistance
Blood and lymphatic system disorders		Leukopenia Eosinophilia	Thrombocytopenia Neutropenia	Pancytopenia Haemolytic anaemia Agranulocytosis
Immune system disorders			Angioedma Hypersensitivity (see section 4.4)	Anaphylactic shocka Anaphylactoid Shock a (see section 4.4)
Metabolism and nutrition disorders		Anorexia	Hypoglycaemia particularly in diabetic patients (see section 4.4)	Hyperglycaemia Hypoglycaemic coma (see section 4.4)
Psychiatric disorders*	Insomnia	Anxiety Confusional state Nervousness	Psychotic reaction (with e.g. hallucinations, paranoia) Depression Agitation Abnormal dreams Nightmares	Psychotic disorders with self- endangering behaviour including suicidal ideation or suicide attempt (see section 4.4)
Nervous system disorders*	Headache Dizziness	Somnolence Tremor Dysgeusia	Parasethesia Convulsions (see section 4.3 and 4.4)	Peripheral sensory neuropathy (see section 4.4) Peripheral sensory motor neuropathy (see section 4.4) Parosmia including anosmia Dyskinesia Extrapyramidal disorder Ageusia Synocope Benign intracranial hypertension
Eye disorders*			Visual disturbances such as blurred vision (see section 4.4)	Transient vision loss (see section 4.4)
Ear and Labyrinth disorders*		Vertigo	Tinnitus	Hearing loss Hearing impaired
Cardiac disorders**			Tachycardia Palpitation	Ventricular tachycardia, which may result in cardiac arrest Venticular arrhythmia and torsade de pointes (reported predominantly in patients with risk factors of QT prolongation) , electrocardiogram QT prolonged (see sections 4.4 and 4.9)
Vascular disorders**	Applies to i.v. form only: Phlebitis		Hypotension
Respiratory, thoracic and medistinal disorders		Dyspnoea		Bronchospasm Pneumonitis allergic
Gastro-intestinal disorders	Diarrhoea Vomiting Nausea	Abdominal pain Dyspepsia Flatulence Constipation		Pancreatitis Diarrhoea – haemorrhagic which in very rare cases may be indicative of enterocolitis, including pseudomembranous colitis (see section 4.4)
Hepatobiliary disorders	Hepatic enzyme Increased (ALT/AST, alkaline phosphatase, CGT)	Blood bilirubin increased		Jaundice and severe liver injury, including cases with fatal acute liver failure, primarily with severe underlying diseases (see section 4.4) Hepatitis
Skin and subcutaneous tissue disordersb		Rash Pruritus Urticaria Hyperhidrosis		Toxic epidermal necrolysis Stevens-Johnson syndrome Erythema multiforme Photosensitivity reaction (see section 4.4) Leukocytoclastic vasculitis Stomatitis
Musculoskeletal and connective tissue disorders*		Arthralgia Myalgia	Tendon disorders (see sections 4.3 and 4.4) including tendinitis (e.g. Achilles tendon) Muscle weakness which may be of special importance in patients with myasthenia gravis (see section 4.4)	Rhabdomyolysis Tendon rupture (e.g. Achilles tendon) (see sections 4.3 and 4.4) Ligament rupture Muscle rupture Arthritis
Renal and Urinary disorders		Blood creatinine increased	Renal failure acute (e.g. due to interstitial nephritis)
General disorders And administration site conditions*	Applies to i.v. form only: Infusion site reaction (pain, reddening), dryness of mouth.	Asthenia	Pyrexia	Pain (including pain in back, chest, and extremities)

^a Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose
^bMucocutaneous reactions may sometimes occur even after the first dose
Other undesirable effects which have been associated with fluoroquinolones administration
include:
• attacks of porphyria in patients with porphyria.
* Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some
cases irrespective of pre-existing risk factors (see Section 4.4).
** Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).

Reporting of suspected adverse reactions

Reporting of suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
To report any side effects:
Saudi Arabia:
The National Pharmacovigilance Centre (NPC):
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa/
Other GCC states:
Please contact the relevant competent authority

According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of levofloxacin tablets are central nervous symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions. CNS effects include confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.

In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body.

No specific antidote exists.

Pharmacotherapeutic group: Quinolone antibacterials - Fluoroquinolones
ATC code: J01MA12

Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S(-)
enatiomer of the racemic drug substance ofloxacin.

Mechanism of action
As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex
and topoisomerase IV.
 

Mechanism of resistance
Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both
type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as
permeation barriers (common Pseudomonas aeruginosa) and efflux mechanisms may affect
susceptibility to levofloxacin.
Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the
mechanism of action, there is generally no cross-resistance between levofloxacin and other
classes of antibacterial agents.
 

Breakpoints
The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from
intermediately susceptible organisms and intermediately susceptible from resistant organisms
are presented in the below table for MIC testing (mg/L).
EUCAST clinical MIC breakpoints for levofloxacin (version 2.0, 2012-01-01)

Pathogen	Susceptible	Resistant
Entecobacteriaceae	≤ 1 mg/L	>2 mg/L
Pseudomonas spp.	≤ 1 mg/L	>2 mg/L
Acinetobacter spp.	≤ 1 mg/L	>2 mg/L
Staphylococcus spp.	≤ 1 mg/L	>2 mg/L
S. pneumoniae 1	≤ 2mg/L	>2 mg/L
Streptococcus A, B, C ,G	≤ 1 mg/L	>2 mg/L
H. influenzae 2,3	<1 mg/L	>1 mg/L
M. catarrhalis 3	<1 mg/L	>1 mg/L
Non-species related breakponts 4	≤ 1 mg/L	>2 mg/L

¹The breakpoints for levofloxacin relate to high dose therapy.
²Low-level fluoroquinolone resistance (ciprofloxacin MICs of 0.12 -05 mg/l) may occur but there
is no evidence that this resistance is of clinical importance in respiratory tract infections with H.
influenza.

³ Strains with MIC values above the susceptible breakpoint are very rare or not yet reported. The identification and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant.
⁴ Breakpoints apply to an oral dose of 500 mg x 1 to 500 mg x 2 and an intravenous dose of 500 mg x 1 to 500 mg x 2..
The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

COMMONLY SUSCEPTIBLE MICROORGANISMS
Aerobic Gram-positive bacteria
Bacillus anthracis
Staphylococcus aureus* methicillin susceptible
Staphylococcus saprophyticus
Stretococci, groups C and G
Streptococcus agalactiae
Streptococcus pneumoniae*
Streptococcus pyogenes*
Aerobic Gram-negative bacteria
Eikenella corrodens
Haemophilus influenzea
Haemophilus para-influenzae
Klebsiella oxytoca
Moraxella catarrhalis
Pasteurella multocida
Proteus vulgaris
Providencia rettgeri
Anaerobic bacteria
Peptostreptococcus
Other
Chlamydophila pneumoniae
Chlamydophila psittaci
Chlamydia trachomatis
Legionella pneumophila
Mycoplasma pneumoniae
Mycoplasma hominis
Ureaplasma urealyticum

SPECIES FOR WHICH ACQUIRED RESISTANCE MAY BE A PROBLEM
Aerobic Gram-positive bacteria
Enterococcus faecalis
Staphylococcus aureus methicillin-resistant#
Coagulase negative Staphylococcus spp
Aerobic Gram-negative bacteria
Acinetobacter baumanni

Citrobacter freundi
Enterobacter aerogenes
Enterobacter cloacae
Escherichia coli
Klebsiella pheumoniae
Morganella morganii
Proteus mirablis
Providencia stuartii
Pseudomonas aeruginosa
Serratia marcescens
Anaerobic bacteria
Bacteroides fragilis

INHERENTLY RESISTANT STRAINS
Aerobic Gram-positive bacteria
Enterococcus faecium
#Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin.

Absorption
Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma
concentrations being obtained within 1 – 2 h. The absolute bioavailability is 99 - 100%.
Food has little effect on the absorption of levofloxacin.
Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.

Distribution
Approximately 30 – 40% of levofloxacin is bound to serum protein. The mean volume of
distribution of levofloxacin is approximately 100 l after single and repeated doses, indicating
widespread distribution into body tissues.

Penetration into tissues and body fluids:
Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid alveolar
macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin
has poor penetration intro cerebro-spinal fluid.

Biotransformation
Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin
and levofloxacin N-oxide. These metabolites account for < 5% of the dose excreted in urine.
Levofloxacin is stereochemically stable and does not undergo chiral inversion.

Elimination
Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly
from the plasma (t_1⁄2: 6 – 8 h). Excretion is primarily by the renal route (>85% of the
administered dose).
The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175
+/- 29.2 ml/min.
There are no major differences in the pharmacokinetics of levofloxacin following intravenous
and oral administration, suggesting that the oral and intravenous routes are interchangeable. 

Linearity
Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.

Special populations
Subjects with renal insufficiency
The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal
function renal elimination and clearance are decreased, and elimination half-lives increased as
shown in the table below:
Pharmacokinetics in renal insufficiency following single oral 500 mg dose

Clcr [ml/min]	<20	20 – 49	50 – 80
ClR [ml/min]	13	26	57
t1⁄2 [h]	35	27	9

 

Elderly subjects
There are no significant differences in levofloxacin kinetics between young and elderly subjects,
except those associated with differences in creatinine clearance.

Gender differences
Separate analysis for male and female subjects showed a small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.
Pharmacokinetic/Pharmacodynamics relationships:
The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum
concentration in serum (C_max) or the area under the curve (AUC) and the minimal inhibitory
concentration (MIC).

Non-clinical data reveal no special hazard based on conventional studies of single dose toxicity,
repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.
Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only
effect on foetuses was delayed maturation as a result of maternal toxicity.
Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce
chromosome aberrations in Chinese hamster cells in vitro. These effects can be attributed to
inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange,
unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.
Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses.
Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced
tumour development in a photocarcinogenicity study.
In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and
cavities) in rats and dogs. These findings were more marked in young animals.

Lenova 500 mg film coated tablet contain the following excipients:
Povidone K30, Crospovidone XL, Prosolve 90, Purified Talc, Croscarmellose sodium,
Aerosil200, Magnesium stearate,
Film coat: Opadry Pink 80 w 24704 (FD&C blue/indigo carmine Aluminum lake, Talc, titanium
Dioxide, lecithin(soy), ponceau 4R lake, polyvinyl Alcohol, Erythrosine Aluminum Lake)

Not applicable

3 Years

Store below 30 ̊ C in dry place

Colourless PVC: Plastic film, Transparent, colourless, hard, smooth, no contamination, No
defaults such as holes, folds and grease

Aluminum foil: Aluminium foil, opaque, Hard, smooth, Silvery metallic sheets, dull side
prelacquered, Bright side heat seal lacqured, No contamination, No defaults such as holes,
folds and grease. For printed matter: coloured according to standard sample.

External Box: Flap end carton box, Full creasing, full side seam, properly pasted with distinct
offset printing devoid of any smudging, registration, water or ink marks having area for batch
coding

Insert paper: Distinctly printing devoid of any smudging, water or ink marks

A score line allows adaptation of the dose in patients with impaired renal function.
Any unused product or waste material should be disposed of in accordance with local
requirements.